IP Library › Granted Patent US 9,040,496
Granted Patent B2
US 9,040,496 · App. 14/089,833 · Granted May 26, 2015

Reduction of ALMS1 gene expression or inhibition of altröm protein to induce cardiomyocyte proliferation

Inventors: Daniel Philip Judge (Baltimore, MD); Peter Andersen (Baltimore, MD); Lincoln Takura Shenje (Portland, OR)
Assignee: The Johns Hopkins University
C12N15/1136C12N15/113C12N2310/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,496
App. No.
14/089,833
Granted
May 26, 2015
Kind
B2
Abstract

The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.

Claims (6)

1. A method for inducing proliferation of cardiomyocytes comprising the step of administering an effective amount of an Alstrom syndrome 1 protein (ALMS1) inhibitor, wherein the ALMS1 inhibitor is an antisense oligonucleotide.

2. A method for inducing proliferation of cardiomvocytes in a patient suffering from heart failure, cardiomyopathy, congenital heart disease or cardiac injury comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an siRNA, shRNA or an antisense oligonucleotide.

3. A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an siRNA, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

4. A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is shRNA, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

5. A method for treating heart failure, cardiomyopathy, congenital heart disease or cardiac injury in a patient comprising the step of administering to the patient a therapeutically effective amount of an ALMS1 inhibitor, wherein the ALMS1 inhibitor is an antisense oligonucleotide, and further wherein the ALMS1 inhibitor inhibits ALMS1 expression and/or activity and induces proliferation of cardiomyocytes.

6. A method for inducing proliferation of cardiomyocytes comprising the step of administering an effective amount of an siRNA or shRNA inhibitor of the expression of the ALMS1 gene to result in RNA interference.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2014
From: JUDGE, DANIEL PHILIP; ANDERSEN, PETER; SHENJE, LINCOLN TAKURA
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 033705/0569 →
Continuity (2)
Provisional Application 61730312 · Nov 27, 2012
Related Publication 20140179763A1 · Jun 26, 2014